At present, the clinical studies of various anti-inflammatory drugs and immune-enhancing drugs show that immunotherapy will bring new hope for the treatment of sepsis. In order to further understand the current status of immunotherapy in China, this study aims to understand the current status and standardization of the use of sepsis immunosurveillance and immunotherapy in hospitals through a cross-sectional survey.
Study Type
OBSERVATIONAL
Enrollment
5,000
No intervention is involved in this study
28-day mortality
Time frame: 28 days
Percentage of sepsis patients receiving immune function monitoring
Time frame: 28 days
Percentage of sepsis patients receiving immunotherapy
Time frame: 28 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.